| Full text | |
| Author(s): |
Galvis, Marisol Miranda
[1, 2]
;
Borges, Gabriel Alvares
[3, 2]
;
de Oliveira, Thiago Bueno
[4]
;
de Toledo, Isabela Porto
[3]
;
Castilho, Rogerio Moraes
[2, 5]
;
Silva Guerra, Eliete Neves
[3, 2]
;
Kowalski, Luiz Paulo
[6, 1, 7]
;
Squarize, Cristiane Helena
[2, 5]
Total Authors: 8
|
| Affiliation: | [1] Univ Campinas UNICAMP, Piracicaba Dent Sch, Oral Diag Dept, Piracicaba - Brazil
[2] Univ Michigan, Sch Dent, Lab Epithelial Biol, Dept Periodont & Oral Med, 1011N Univ Ave, Ann Arbor, MI 48109 - USA
[3] Univ Brasilia, Hlth Sci Fac, Lab Oral Histopathol, Brasilia, DF - Brazil
[4] AC Camargo Canc Ctr, Clin Oncol Dept, Sao Paulo - Brazil
[5] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 - USA
[6] AC Camargo Canc Ctr, Dept Head & Neck Surg & Otorhinolaryngol, Sao Paulo - Brazil
[7] Univ Sao Paulo, Med Sch, Head & Neck Surg Dept, Sao Paulo - Brazil
Total Affiliations: 7
|
| Document type: | Review article |
| Source: | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY; v. 150, JUN 2020. |
| Web of Science Citations: | 0 |
| Abstract | |
Background: Despite multiple modalities used to management of head and neck squamous cell carcinoma (HNSCC), disease control remains unsatisfactory. Immunotherapy is emerging as a novel therapeutic approach. This systematic review assesses clinical data regarding immunotherapy efficacy and safety. Methods: Data from 11 clinical trials testing immunotherapy in HNSCC were assessed. We performed the meta-analysis to correlate the overall survival (OS), response rate (RR), adverse effects, HPV status, and PD-L1 expression. Results: Immunotherapy extended OS (hazard ratio = 0.77, p < 0.0001) and RR significantly (risk ratio = 1.41, p = 0.02). Patients with HPV-positive HNSCC exhibited a better RR (risk ratio = 1.29, p = 0.24) and OS (11.5 vs. 6.3 months). PD-L1 positive tumors showed a higher OS (9.9 vs. 6.5 months). Moreover, immunotherapy caused less adverse effects than standard therapy. Conclusion: Our results indicate the benefit of immunotherapy for improving RR and OS of HNSCC patients. The benefit is higher in patients with HPV and PD-L1 positive tumors. (AU) | |
| FAPESP's process: | 16/03248-1 - Mass spectometry based proteomic in oral squamous cell carcinoma in young patients |
| Grantee: | Marisol Miranda Galvis |
| Support Opportunities: | Scholarships in Brazil - Doctorate |
| FAPESP's process: | 17/16347-0 - FUNCTIONAL ANALYSIS OF HPV-RELATED PROTEINS IN ORAL SQUAMOUS CELL CARCINOMA |
| Grantee: | Marisol Miranda Galvis |
| Support Opportunities: | Scholarships abroad - Research Internship - Doctorate |